Navigation Links
NovaVision CEO Named Presenter at the AdvaMed 2008 Conference

BOCA RATON, Fla., Sept. 8 /PRNewswire/ -- NovaVision today announced that the company has been selected to present at the prestigious AdvaMed 2008: The MedTech Conference (, on Monday, September 22, 2008 in Washington, DC.

During the presentation, which falls in the "Next Generation" category, Mr. Rudy Mazzocchi, the newly appointed chief executive officer of NovaVision, will address the increasing use of Vision Restoration Therapy (VRT) among U.S. and global healthcare providers. VRT is a non-invasive medical device cleared by the United States Food & Drug Administration to help restore vision to the millions of underserved people living with impaired sight caused by a stroke or traumatic brain injury (TBI).

Using the science of neuroplasticity -- the brain's ability to rewire itself -- VRT is an in-home personalized restoration therapy that uses light-based stimuli to gradually activate adjacent neurons in the brain responsible for vision. Each patient receives a program that is entirely customized to their own unique visual field deficits. Every month, the patient receives an advanced program to correlate to individual progress. Clinical trials show that nearly 70-80% of all patients show improved vision following therapy, regardless of how long ago their stroke or TBI occurred.

About NovaVision, Inc.

NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically-based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. FDA-cleared in 2003, NovaVision's Vision Restoration Therapy devices work by enhancing neuroplasticity -- the brain's ability to adapt and form new connections to compensate for injury. NovaVision's diagnostic program maps areas where vision may be improved, and the therapy program targets and stimulates regions within the brain's vision-processing areas.

NovaVision VRT(R) is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Data from a recent retrospective study identified that more than 70 percent of patients who underwent VRT for an initial six-month treatment period showed measurable improvements in their vision.

VRT is currently offered at leading neurological, eye and rehabilitation centers nationwide. For more information, please visit or call 1.888.205.0800.


Ellie Kline, Edelman on behalf of NovaVision

Ph. 212-704-4528


SOURCE NovaVision, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer
2. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
3. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
4. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
5. Stoppert Named as President and CEO at Breakthrough Renewable Technology Firm Segetis, Inc
6. Baxa Corporation Named to Inc. 5000 for Second Consecutive Year as One of the Fastest-Growing Private Companies in the US
7. IDIS Opens New American Office in Response to Industrys Growing Need for Pre-Launch Named Patient Programs
8. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
9. Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):